share_log

HC Wainwright & Co. Maintains Buy on Pacira BioSciences, Lowers Price Target to $57

Benzinga ·  Nov 6, 2023 06:32

HC Wainwright & Co. analyst Oren Livnat maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $63 to $57.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment